University of Maryland aims to develop vaccine for common Gram-negative bacteria

The University of Maryland School of Medicine Center for Vaccine Development is joining a research partnership to try to develop a vaccine to combat several types of Gram-negative bacteria that are known for causing infections in hospital patients.

The research partnership will include several American biotechnology companies and a pharmaceutical company based out of Tokyo.

UM professor of medicine Alan S. Cross, MD, and two assistant professors of medicine — Raphael Simon, PhD, and Sharon Tennant, PhD — will lead the Center for Vaccine Development project.

Even though healthcare-associated infections afflict millions of patients a year, there are no licensed vaccines currently available for any of the major HAIs.

"This is a response to a serious unmet need. We think this partnership has enormous potential," said Dr. Cross. "We think we can make a significant dent in the effect these infections have in the U.S., and around the world."



More articles on vaccines:
The first line of defense: 10 steps to boost influenza vaccinations among healthcare workers
Study: Most hospitals do not require staff to get flu shots
Researchers discover how to make flu vaccine more effective for high-risk cancer patients

Copyright © 2024 Becker's Healthcare. All Rights Reserved. Privacy Policy. Cookie Policy. Linking and Reprinting Policy.


Featured Whitepapers

Featured Webinars